CytRx Corp (CYTR) Posts Surprise Q1 Profit
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
- US consumer sentiment near record low as frustration over economy mounts
- 8.0 Mag. Earthquake 14 Km Sw Of Pitaloza Arriba Panama - USGS
- Strong Panama quake shakes nation, but avoids major destruction
- Nio stock jumps after Goldman Sachs upgrade to buy
- Wall Street posts weekly gains with earnings, inflation data on tap
Aegis Capital Keeps CytRx (CYTR) at Buy following Updated Aldoxorubicin Phase 1b/2 Data
May 5, 2014 11:54 AM EDTAegis Capital reiterates its Buy rating and $12 price target on CytRx Corp. (Nasdaq: CYTR) following the presentation of updated progression-free survival (PFS) and overall survival (OS) results from its completed Phase 1b/2 trial of aldoxorubicin in patients with advanced soft tissue sarcoma... More



